This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Bezafibrate oral standard release

Updated 2 Feb 2023 | Fibrates


Oral standard release formulations of bezafibrate

Drugs List

  • bezafibrate 200mg tablets
  • BEZALIP 200mg tablets
  • Therapeutic Indications


    Mixed hyperlipidaemia when statin is contraindicated or not tolerated
    Severe hypertriglyceridaemia with or without low HDL cholesterol

    Bezafibrate is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following:

    Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol.

    Mixed hyperlipidaemia when a statin is contraindicated or not tolerated.



    200mg three times a day.


    Children aged 10 to 18 years (unlicensed)
    200mg once daily, increased according to response to a maximum of three times a day.

    Patients with Renal Impairment

    In adults with renal impairment the dose should be adjusted according to serum creatinine levels or creatinine clearance, as shown below:

    Serum creatinine up to 135 micromol/litre or creatinine clearance greater than 60ml/minute: 200mg three times daily.
    Serum creatinine greater than 135 to 225 micromol/litre or creatinine clearance 40 to 60ml/minute: 200mg twice daily.
    Serum creatinine greater than 225 to 530 micromol/litre or creatinine clearance 15 to 40ml/minute: 200mg daily or on alternate days.
    Serum creatinine greater than 530 micromol/litre or creatinine clearance less than 15ml/minute: Contraindicated.

    Special care is needed in patients with renal impairment, as progressive increases in serum creatinine concentration or failure to follow dosage guidelines may result in myotoxicity (rhabdomyolysis). Discontinue bezafibrate immediately and monitor renal function closely if myotoxicity suspected or creatine kinase concentration increases significantly.

    The Renal Drug Handbook suggests the following doses according to Glomerular Filtration Rate (GFR):
    GFR 40 to 60ml/minute: 400mg daily.
    GFR 15 to 40ml/minute: 200mg every 24 to 48 hours.
    GFR less than 15ml/minute: Avoid.

    Alternative sources suggest the following dose reductions for children aged 10 to 18 years:
    Renal impairment (estimated glomerular filtration rate 15 to 60 ml/minute/1.73 square metre): Reduce dose
    Renal impairment (estimated glomerular filtration rate less than 15 ml/minute/1.73 square metre): Avoid.

    Patients with Hepatic Impairment

    Bezafibrate is contraindicated in patients with severe hepatic impairment (other than fatty infiltration of the liver associated with raised triglyceride values).

    Additional Dosage Information

    Patients susceptible to the gastrointestinal effects of bezafibrate should initiate treatment by slowly increasing the dose over five to seven days.

    The response to therapy is normally rapid, although a progressive improvement may occur over a number of weeks. Treatment should be withdrawn if an adequate response has not been achieved within three to four months.


    Children under 10 years
    Creatine kinase levels over 5 times upper limit of normal
    Photoallergic or phototoxic reactions to fibrates
    Gallbladder disease
    Nephrotic syndrome
    Renal dialysis
    Renal impairment - creatinine clearance below 15ml/minute
    Renal impairment in children 10 to 18 years - eGFR <15ml/minute/1.73m sq
    Severe hepatic impairment

    Precautions and Warnings

    Children aged 10 to 18 years
    Family history of hereditary muscular disorders
    High alcohol intake
    Major surgery
    Patients over 65 years
    Severe infection
    Severe trauma
    Diabetes mellitus
    Electrolyte imbalance
    Hereditary muscular disorder
    History of muscular toxicity secondary to fibrates
    History of muscular toxicity secondary to HMG-CoA reductase inhibitors
    History of non-traumatic rhabdomyolysis
    Renal impairment - creatinine clearance 15-60ml/minute

    Reduce dose in patients with creatinine clearance of 15-60 ml/min
    Advise ability to drive/operate machinery may be affected by side effects
    Correct hypothyroidism before treatment
    Exclude/correct secondary causes of dyslipidaemia prior to treatment
    If cholelithic symptoms occur perform appropriate diagnostic procedures
    Monitor antidiabetic drug treatment
    Monitor creatine kinase levels in patients at risk of rhabdomyolysis
    Monitor diabetic patients during initiation of therapy
    Advise patients to report muscle pain/tenderness/weakness
    Discontinue if myopathy is suspected
    Discontinue if an adequate response not achieved within 3 months
    Discontinue if creatine kinase concentration increases significantly
    Discontinue immediately if rhabdomyolysis occurs
    Dietary restrictions should be maintained
    Female: Ensure adequate contraception during treatment

    Bezafibrate should be used as an adjunct to diet and measures such as physical activity, weight loss and adequate treatment of other metabolic disorders (e.g. diabetes, gout).

    Secondary causes of dyslipidaemia, such as uncontrolled type 2 diabetes mellitus, hypothyroidism, nephritic syndrome, dysproteinaemia, obstructive liver disease, pharmacological treatment, alcoholism should be adequately treated before bezafibrate therapy is initiated.

    Bezafibrate is known to alter the composition of bile and isolated reports of gallstones have been reported.

    Oestrogens may lead to a rise in lipid levels, prescribing of bezafibrate in patients taking oestrogens or oestrogen-containing contraceptives must be critically considered on an individual basis.

    Pregnancy and Lactation


    Bezafibrate is contraindicated in pregnancy.

    At the time of writing there is limited data from the use of bezafibrate in pregnant women.

    Bezafibrate is not recommended during pregnancy and in women of childbearing potential not using contraception.

    Schaefer (2007) states inadvertent treatment with bezafibrate does not necessitate termination of pregnancy or requirement for invasive diagnostic procedures. It is unknown if it crosses the placenta.

    Animal studies are sufficient with respect to reproductive toxicity.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Bezafibrate is contraindicated in breastfeeding.

    At the time of writing there is insufficient information on the excretion of bezafibrate or its metabolites in human milk. A risk to the infant cannot be excluded.

    A decision must be made whether to discontinue breastfeeding or to discontinue bezafibrate therapy taking into account the benefit of breastfeeding for the infant and the benefit of therapy for the women.

    Schaefer (2007) suggests that there is no disadvantage to the mother if treatment is stopped during breastfeeding.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Abdominal distension
    Abdominal pain
    Acute renal failure
    Anaphylactic reaction
    Creatine phosphokinase increased
    Decreased alkaline phosphatase
    Decreased appetite
    Erectile dysfunction
    Erythema multiforme
    Gamma glutamyl transferase (GGT) decreased
    Gamma glutamyl transferase (GGT) increased
    Gastro-intestinal disturbances
    Haemoglobin decrease
    Hypersensitivity reactions
    Increase in serum transaminases
    Increased platelet count
    Interstitial lung disease
    Muscle cramps
    Muscle weakness
    Peripheral neuropathy
    Serum creatinine increased
    Stevens-Johnson syndrome
    Thrombocytopenic purpura
    Toxic epidermal necrolysis
    White blood cell count decreased


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: August 2016

    Reference Sources

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    The Renal Drug Handbook. Fourth Edition (2014) ed. Ashley, C and Dunleavy, A, Radcliffe Publishing Ltd, London.

    Summary of Product Characteristics: Bezalip 200mg tablets. Actavis UK Ltd. Revised October 2015.

    NICE Evidence Services Available at: Last accessed: 21 June 2017

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.